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hypercaloric diet, and four had 40 g of animal proteins daily. In five
out of six cases, no significant urea release into hepatic veins was
observed, whereas in five out of seven cases a significant urea
output into the internal jugular veins was detected (0.5 0.1
mmole/liter). These results were compared to those in seven sub-
jects with normal renal function on 50 g of animal protein intake
daily, who showed a significant urea release into the hepatic veins
(0.15 0.09 mmole/liter). In four cases where blood from jugular
veins was obtained, no urea release from the brain was observed.
Conclusion. Data presented here indicate that in chronic renal
insufficiency the human brain can replace hepato-splancnic urea
synthesis.
Bemodynamic alterations in hypertension of early renal paren-
chymal disease. F. Volvo, G. Onesti, M. Fernandes, 0. Bates, R.
Fiorentini, K. E. Kim, and C. Swartz. Hahnemaun Medical Col-
lege, Philadelphia, Pennsylvania, U.S.A., e Divisione Clinicizzata
di Nefrologia Medica, Istituti Ospitalieri di Verona, Italy. The
systemic and renal hemodynamic patterns have been investigated
in 37 adult patients with chronic renal parenchymal disease who
have normal GFR or early renal insufficiency. Twenty-two pa-
tients were hypertensive and 15 were normotensive. The mean
GFR values were 64 24 mI/mm in the first group and 55 30 ml!
mm in the second group. The hematocrit was 38 6 and 38 5,
respectively. Both cardiac index and total peripheral resistance
were significantly higher in hypertensive patients than in those
with normal blood pressure. The hypertensive group was arbitrar-
ily divided into two subgroups according to the known duration of
hypertension (more or tess than two years). No significant differ-
ence in mean arterial pressure and GFR values was recorded in the
two groups. The cardiac index was higher, and the total peripheral
resistance was lower in early hypertensive patients rather than in
those with long-lasting hypertension. No correlation was observed
between mean arterial pressure and total blood volume or GFR in
the two groups. These results show that the hypertension observed
in early renal parenchymal disease is not related to the decrease in
renal function or to anemia but seems to depend partly on the
increased cardiac output.
Influence of the ultrafiltration on plasma renin activity and
adrenergic system. A. Zuccalà, F. Degli Esposti, C. Chiarini, A.
Santoro, L. Catizone, P. Zucchelli. Reparto di Nefrologia e Dial-
isi, Ospedale M. Malpighi, Bologna, Italia. The influence of effi-
cient ultrafiltration without dialysis fluid was compared to the
standard dialysis technique in two groups of four patients with
chronic renal failure on maintenance hemodialysis. The experi-
ment was carried out for two months. Clinostatic plasma renin
activity (PRA), plasma concentration of noradrenaline (NA) and
adrenaline (A), and the Valsalva maneuver were evaluated before
and after the period of ultrafiltration at the beginning and at the end
of the experiment. The behavior of these parameters was related to
changes of blood pressure and body weight. The rapid weight loss
was well tolerated during ultrafiltration with oaly a significant
increase of plasma catecholamine concentration; on the contrary,
patients treated with ultrafiltration and dialysis showed no signifi-
cant increase of NA and A levels, and they frequently became
hypotensive. No relationship was observed between changes in
PRA and those in body weight and blood pressure. The data
suggest that rapid removal of catecholamines during standard
dialysis hinders the compensatory increase of the adrenergic activ-
ity and is responsible for hypotension.
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Queries on the etiology of Bartter's syndrome and results of
treatment in six patients. F. M. Desmit, J. Elema, J. J. Brown, A.
F. Lever, J. I. S. Robertson, R. Fraser. Ped. Clin. Free University
Hospital, Amsterdam, andM. R. C. Blood Pressure Unit, Western
Infirmary, Glasgow, GB. There is still a controversy regarding the
etiology of Bartter's syndrome. In contrast to most investigators,
we did not find a high aldosterone production unless a low sodium-
diet resulted in sodium depletion. ACTH gave a brisk increase in
aldosterone production. In each of six patients, daily albumin
infusions for two to four weeks resulted in marked improvement in
general condition, near normalization of serum potassium and
plasma angiotensin II concentrations. Then, the pressor effect of
angiotensin II infusion returned, but the stimulation on plasma
aldosterone remained blunted. This suggested a partial inability of
the adrenal glands to increase aldosterone production on angioten-
sin II stimulation. Mineralcorticoids, however, did not change the
sodium-potassium balance. Indomethacin (introduced for treat-
ment in Bartter's syndrome by Verberckmoes, assuming a primary
hyperproduction of prostaglandins with secondary hyperaldoste-
ronism) also resulted in a dramatic improvement in our patients:
well being, muscle strength, growth velocity ('/3 to I cm/month, for
6 to 18 months), serum potassium (2—2.5 to 3—4 mEq/liter), total
body potassium (39 to 59 mEq/kg of body wt), decrease in anglo-
tensin 11(400—77(1) to 40—120 pg/mi, even when in two patients
sodium-restricted diet had prevented a positive sodium balance).
The following experiments were then repeated: I) In one patient,
9a-fluorohydrocortisone now gave a normal response on electro-
lyte balance (due to abolishing by indomethacin of the prostaglan-
din effect on the distal tubule?). 2) The effect of angiotensin II
infusions on plasma aldosterone levels remained blunted, even in
one patient who had been treated for one year (serum potassium>
3.5 mEq/liter). Plasma angiotensin increased from 76 to 619 pg/nil
(N > 35), plasma aldosterone from 11 to 23 ng/l00 ml. 3) The
discontinuation of indomethacin, given during three months,
caused an endogenous increase in angiotensin II and aldosterone
levels; an increase occurred in angiotensin II (from 171 to 1028 pg/
ml) and plasma aldosterone (from 7 to 12 ng/l00 ml) within two
days. These three observations cannot be readily explained by a
primary hyperproduction of prostaglandins. Hyperproduction of
prostaglandins could be secondary to increased angiotensin II
levels. Renin-angiotensin levels, under certain circumstances,
could be independent of sodium balance if both stretch receptors
(albumin infusions) and chemical receptors (effect of prostaglan-
dins on intrarenal circulation and thus on chemical composition of
tubular fluid reaching the macala densa) are accepted as trigger
mechanisms. Treatment with indomethacin, 3 mg/kg/day (orally, 4
hourly; or rectally, 8 hourly) with additional potassinm chloride (4
mEq/kg/day) has been very satisfactory in our patients, whose
ages range from 6 to 23 yr.
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Kidney perfusion measurement with the rubidium-81-to-kryp-
ton-81m (8lRb/SlmKr) ratio.D. de Zeeuw, J. van der Wjk,.and G.
van Herk. Department of Internal Medicine and Department of
Experimental Surgery, University Hospital, Groningen, The Neth-
erlands. Each of the conventional methods for measuring kidney
perfusion has its typical disadvantages. It is either invasive (Xenon
wash out, dye dilution), aspecific (renography), non-selective (ex-
tra-renal perfusion flow), or non-quantitative (serial iv. pyelogra-
phy). During our study on the relation between nephroptosis and
hypertension, we felt the need for a technique that would monitor
renal blood flow during changes in posture. The slRb/mKr ratio
method, as described by Van Herk, seems ideal for this purpose
and therefore has been tested in a series of animal experiments.
This method profits from the unique physical properties of the
short-lived radioactive tracer rubidium 81, a potassium analogue,
which we prepare in the cyclotron of the University of Groningen.
After i.v. injection, 81Rb concentrates in the kidneys and muscle
tissue. Here rubidium 81 continuously generates, by its decay, the
radioactive inert gas, krypton 81m. The 8lmKr formed diffuses over
the organ and is carried away with the organ blood flow. The ratio
of the activities of 81Rb and 8'Kr, measured over the organ, is
proportional to the amount of blood flowing through the organ per
unit of tissue mass and per unit of time. We measured the perfu-
sion of a dog kidney with the BlRb/mKr ratio method in five
experiments. The results were compared with a Doppler flow
measurement, performed simultaneously. In order to achieve this,
the kidney of a heparinized dog (fluothane anesthesized), had been
transplanted and was anastomosed to the femoral artery and vein
with silicone tubing. Thus, it was possible to regulate and regis-
trate the kidney blood flow around the arterial silicone tube, with a
clamp and a Doppler device, respectively. In all five experiments,
the slRb/mKr ratio, indeed, appeared to rise with increasing
perfusion and to drop with decreasing perfusion. Moreover, the
ratio-values correlated well with the Doppler measurements (r =
0.98 with 19 flow values, exp. 1). In conclusion, these results
suggest that the slRb/mKr ratio accurately reflects renal blood
flow variations in this experimental setup. After further study, this
could lead to an accurate quantitative kidney perfusion measure-
ment for the clinician, with the advantages of 1) monitoring
changes of kidney perfusion in time (up to 1 hr after injection),
2) being non-invasive, and 3) being of little inconvenience to the
patient.
Effect of mannitol and furosemide on kidney function postopera-
tively after renal transplantation in a double blind randomized
study. Ph. P. N. M. Diderich, L. D. F. Lame(jer, D. L. West-
broek. University Hospital, Rotterdam, The Netherlands. The
protective effect of furosemide and mannitol on kidney function in
patients with imminent acute tubulus necrosis is still a matter of
discussion. In a retrospective study, it was shown that 25% manni-
tol (200 cc) and furosemide (80 mg) given to kidney transplant
recipients resulted in better kidney function directly postoperative-
ly. Out of 15 subsequent patients without diuretic treatment, 9
(60%) developed acute tubular necrosis (ATN), the diagnosis being
based on clinical criteria. Out of the 14 treated patients only 1
patient (7%) developed ATN. Hover, a prospective random-
ized, double blind study showed completely different results. Out
of 19 patients treated with mannitol and furosemide, 6 patients
(32%) developed ATN, whereas 5 out of 16 patients (31% without
treatment) developed ATN. Both groups in the prospective study
were identical regarding mean age of donor, mean total warm
ischemia time and mean cold ischemia time. In the retrospective
study, the mean donor age was slightly lower than in the untrerted
group, and the mean warm ischemic time was slightly shorter.
Conclusion: In this group of patients, prevention of acute tubular
necrosis after kidney grafting by the combination of mannitol-
furosemide therapy in the dosage used could not be proven.
Glomerular localization of immune complexes with known size
and composition. A. K)Jlstra, D. W. Knutson, M. R. Daha, and L.
A. van Es. Department of Nephrology, University Hospital, Lei-
den, The Netherlands. Once deposited in the glomerulus, circulat-
ing immune complexes can initiate a sequence of events ultimately
resulting in glomerular injury. However a large variety of immune
complexes occurs in the circulation, it is not yet known which
complexes localize in the glomerulus. To study this question, we
investigated the fate of in vitro prepared immune complexes after
injection into rats. Immune complexes were prepared by reacting
DNP-conjugated proteins with specific goat anti-DNP-IgG. Size
and composition of the complexes were analyzed by sucrose
density gradient ultracentrifugation, using double isotopic mark-
ers. Renal localization of immune complexes was studied by
immunofluorescence microscopy for antigen, antibody, and C3. In
vivo administered complexes formed with DNP conjugated rabbit
serum albumin and having a sedimentation rate below 19S could
not be detected in the kidney. Strong mesangial localization of
soluble immune complexes was seen when the following criteria
were fullifiled: a) high immune complex doses were injected (>3.1
mg of IgG/lOO g of body wt), b) the antibody/antigen ratio of the
complexes exceeded two, c) an antigen was used with many DNP-
groups (DNP17-BTG), d) the sedimentation rate of the complexes
ranged between 19 and 200S. The soluble immune complexes that
were most avidly cleared from the circulation by the hepatic
phagocytes showed the strongest mesangial localization, suggest-
ing a resemblance between the two cell types. The deposition of
these complexes was followed by a weak mesangial C3 fixation.
Poorly soluble and insoluble immune complexes with a sedimenta-
tion rate above 200S do not become localized in the glomerular
mesangium but become temporarily localized as micro-emboli in
the lumen of peritubular and glomerular capillaries. It can be
concluded from this study that both the composition and size of a
circulating immune complex determine whether a complex will
become localized in the mesangium of the glomerulus. A localiza-
tion within the wall of the glomerular capillaries could not be
detected by immunofluorescence.
Effect of prostaglandin (PG) synthesis inhibition on sodium
excretion in the conscious rat. N. Lameire, M. Mussche, S.
Ringoir, I. Leusen. Department of Nephrology, University Hospi-
tal, Gent, Belgium. In order to define the effect of PG release
during extracellular volume (ECV) expansion with either an iso-
tonic Ringer or a 2.5% glucose solution, a comparison was made of
the natriuretic and renal hemodynamic response in conscious rats
before and after the acute iv. administration of two different
inhibitors of prostaglandin (PG) synthesis, either meclophenamate
(M) or indomethacin (I), 5 mg/kg, in three different experimental
settings. In a first group of experiments (N = 24), animals previ-
ously expanded to 5% body weight during 60 mm with 2.5%
glucose were given either M (N = 8), I (N = 8), or the diluent (D)(N = 8) during continuous expansion. PG inhibitors did not alter
glomerular filtration rate (GFR), measured by inulin clearance, or
renal plasma flow (RPF), measured by PAH clearance. Sodium
excretion remained unchanged after PG inhibition (3.66 in control
vs. 3.60 Eq/min after I and vs. 2.94 Eq/min after M, respec-
tively; P > 0.05). In a second group of experiments (N = 24),
control measurements were obtained after 5% body wt expansion
during 60 mm with isotonic Ringer, and experimental measure-
ments were obtained after PG inhibition with continuous Ringer
expansion. No change in GFR, RPF, or sodium excretion was
observed after either D or I (P > 0.05); however, a fall in both
PAH clearance and sodium excretion were observed after M (RPF
decreased from 9.04 in control to 6.90 mI/mm, and sodium excre-
tion decreased from 21.0 to 14.5 .sEq/min; P < 0.05). GFR re-
mained unchanged. In a third group of experiments (N = 24), the
PG inhibitors or the diluent were administered in hydropenia and
before massive acute ECV expansion with Ringer was started.
Experimental clearances were obtained after 60 mm of a 10% body
wt expansion. Sodium excretion was similar in control and PG-
inhibited rats after the Ringer-loading, despite the fact that the
increase in both GFR and RPF, observed in the control animals,
did not occur in the PG-inhibited animals. The mean increase in
absolute sodium excretion was 25.2 rEq/min after D, 23.4 Eq/
mm after I, and 22.0 Eq/min after M (P > 0.05). These data in
conscious rats do not confirm previous results obtained in dogs
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suggesting that PG inhibition is natriuretic in both water and
continued saline diuresis. In conscious rats, sodium excretion
during continued water diuresis is unchanged after PG inhibition
with I or M. However, during continued saline diuresis, a de-
creased sodium excretion, together with a fall in RPF after PG
inhibition with M only, is observed. Administration of PG inhibi-
tors before the onset of an acute Ringer-loading did not prevent the
normal natriuretic response, despite a blunted renal vasodilatation.
The latter results suggest that under these circumstances only the
inhibition of PG release may be associated with a natriuresis.
Treatment of the hemolytic uremic syndrome (HUS): Compari-
son of the results of heparin treatment with the results of strepto-
kinase treatment. L. Monnens, J. van Collenburg, M. de Jong, H.
Zoethont, P. van Wieringen. Departments of Pediatrics, Univer-
sity Hospital, Nj/megen, and University Hospital, Rotterdam, The
Netherlands. The best treatment of the hemolytic uremic syn-
drome (HUS) in childhood remains uncertain. Arguments for the
use of heparin to prevent continuing intrarenal coagulation are
evident. As fibrinolytic therapy can lyse thrombi in the kidney, this
form of therapy seems the most rational approach. In a prospec-
tive study, the results of the treatment of 35 children by heparin at
the University of Rotterdam are compared with the results of 38
children treated by streptokinase at the University of Nijmegen.
No significant difference could be shown either in the age or in the
clinical grading of severity between both groups. Each group
received the same symptomatic treatment (early peritoneal dialys-
is, transfusion of packed cells). The acute mortality rate was 2 out
of 35 in the group treated by heparin (group H) and 3 out of 38 in
the group treated by streptokinase (group S). Two years after the
acute phase, a follow-up study was performed (quantification of
hematuria in fresh uncentrifuged urine, proteinuria, concentrating
capacity, endogenous creatinine clearance, blood pressure). Pro-
teinuria (> 150 mg/24 hr) was seen in eight children of group H and
in two children of group S (P = 0.07). Systolic and diastolit
hypertension was more frequent in group H (P < 0.05). Eight
children had systolic hypertension in group H, one in group S.
Five children showed diastolic hypertension in group H. Diastolic
hypertension was absent in group S. Systolic blood pressure was
considered elevated when > 115 mm Hg between 6 months and 1
yr of age, > 120 mm Hg between 1 and 5 yr, > 130 mm Hg
between 6 and 9 yr, 140mm Hg between 10 and 15 yr. Diastolic
blood pressure higher than 90 mm was increased. The other data
showed no significant difference. This study suggests the superior-
ity of fibrinolytic treatment in children with HUS. Complications
of streptokinase therapy were scarce.
Clinical importance and specificity of antibodies directed against
the vascular endothelium of renal allografts. L. C. Paul, A. van
Leeuwen, J. J. van Rood, L. A. van Es, and J. de Graeff.
Departments of Nephrology and Immunohaematology, University
Hospital, Leiden, The Netherlands. Graft failure occurs mainly
because of vascular rejection, for which the humoral immune
response is thought to be mainly responsible. In an attempt to
detect antibodies directed against the vascular endothelium of the
donor kidney, we investigated sen collected from 63 transplanta-
tion patients before and during the first six weeks after transplanta-
tion. Such antibodies were demonstrated by indirect immunofluo-
rescence with the use of a kidney biopsy specimen taken prior to
transplantation as substrate. Sera of nine recipients showed in
vitro fixation of antibodies of the endothelium of the peritubular
capillaries. In all cases, the presence of these antibodies was
associated with biopsy-proven vascular rejectioii; in eight cases
these rejections were irreversible. Eight patients also lost the graft
because of vascular rejection, but we were unable to demonstrate
anti-endothelial cell antibodies in this group. In five out of nine
cases with anti-endothelial cell antibodies in the serum, we found
evidence of in vivo fixation of antibodies along the vascular endo-
thelium and sometimes within the vessel walls in post-transplanta-
tion biopsy specimens. In two cases, we failed to demonstrate
these antibodies. In two other cases, a biopsy specimen was not
available. In three out of four cases, these antibodies were isolated
from the removed graft by acid elution. Screening of the sera with
anti-endothelial cell antibodies showed multispecific lymphocyto-
toxic antibodies in six patients; one patient showed antibodies
against HLA-2, although this antigen was not present on the graft,
and two patients did not show lymphocytotoxic antibodies.
Absorption of these sera with selected and pooled platelets elimi-
nated the lymphocytotoxic activity, whereas the immunofluores-
cence on kidney sections remained positive, thus, indicating the
presence in these sera of antibodies against antigens other than
HLA-A, HLA-B, or HLA-C. In one case, the anti-endothelial
antibodies could be absorbed with group-B erythrocytes. This
patient had received a kidney incompatible for blood group B.
These results demonstrate the production of antibodies directed
against the endothelium of the peritubular capillaries in patients
with poor graft survival. These antibodies might play an important
role in the pathogenesis of graft rejection at the level of the
peritubular capillaries.
Effective treatment of hypertensive crisis with slow infusion of
diazoxide. Th. Thien, F. Huysmans, P. G. G. Gerlag, R. A. P.
Koene, and P. G. A. B. Wjjdeveld. Department of Nephrology,
University Hospital Njj,negen, The Netherlands. Diazoxide, a
benzothiadiazine compound without diretic activity, acts as a
vascular smooth muscle relaxant by which it decreases peripheral
resistance. The drug is strongly bound to albumin and is only
active in its free form. Therefore, it is recommended to administer
the drug as a bolus injection (10 to 30 sec). Free diazoxide would
then reach the resistant vessels and give vasodilation, before it is
bound to albumin. Recent reports have described hypotension and
myocardial ischemia after bolus injection. Because of those side
effects and contradictory reports in the literature, we studied the
effect of slow (20 to 30 mm) diazoxide infusion. Blood pressures
were measured with the Arteriosonde 1216 (Roche), on the right
arm of the supine patient. The total amount administered was S
mg/kg, and the rate of infusion was 15 mg/nun. Before starting the
infusion, blood pressure was registered during 30 min. The effects
were calculated as the mean of at least three readings, 30 min, 60
min and 8 hr after start of the infusion, and were compared with
the mean of five readings before the infusion. Group A consisted
of 20 patients with chronic non-malignant hypertension. Group B
consisted of 20 patients with a hypertensive crisis. Group C was
the control group of 15 patients with hypertensive crisis, who were
treated with a bolus injection of diazoxide within 10 sec. In group
A, mean blood pressure decreased from 182/116 before to 149/90,
150'93, and 162/101 mm Hg after 30 mm, 60 min, and 8 hr. In group
B, mean blood pressures were 198/133, 163/99, 166/103, and 163/
109 mm Hg, respectively. In group C, mean blood pressures were
207/131, 167/104, 167/105, and- 173/113 mm Hg, respectively.
Hypotension and angina pectoris were not observed. Three
patients complained of nausea, and four patients developed tachy-
cardia, that reached well to propranolol (0.2 mg/kg body wt, iv.).
The hypotensive effect of the slow infusion was comparable to that
of the bolus injection. One patient neither responded to the infu-
sion, nor to three bolus injections. Conclusion: Slow infusion of
diazoxide is an effective and safe treatment. It is preferable to
bolus injections, since blood pressure decreases more gradually
and the infusion can be interrupted at any time.
Pharmacokinetic aspects of digoxin in patients on chronic inter-
mittent hemodialysis and its clinical consequences. W. J. F. van
der Vijgh and P. L. Oe. Departments of Internal Medicine and
Nephrology, University Hospital, Free University, Amsterdam,
The Netherlands. Digoxin often will be prescribed in patients with
cardiovascular disease who are on chronic intermittent hemodialy-
sis (CIH). Since digoxin is excreted primarily by the kidneys, it
must be administered cautiously to this group of patients in order
to avoid intoxication by the drug. The introduction of modem high
capacity dialyzers for CIH and the scarce pharmacokinetic data
concerning digoxin in patients on CIH with mainly low capacity
dialyzers stimulated the study of important pharmacokinetic
parameters like half-life, apparent volume of distribution, and
clearance of digoxin in these patients between and during hemo-
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dialyses with high capacity dialyzers. The data obtained may
contribute to a better digitalization of patients on CIH and may
assist in answering the question of a possible use of hemodialysis
in severe digoxin intoxication. Nine patients on CIH, of which
eight (no. 1—8) were never treated with digoxin before, gave their
verbal consent to the investigation. All patients, except no. 9,
received a first i.v. loading dose of 2 ml (0.5 mg) Lanoxin®
(digoxin) one hour after the end of hemodialysis. A second i.v.
loading dose (the only one in patient no. 9) of 2 ml Lanoxin® was
administered about 24 hr later to all patients. Multiple blood
samples were taken after each injection and during hemodialysis.
All samples were analyzed by radioimmunoassay for digoxin
(SchwarzlMann Digoxin-'251 Radioimmunoassay kit, Cat. No.
0750-06, with a modified procedure). The following was observed
between dialyses: the mean half-life was 88.8 hr, the apparent
volume was decreased compared to patients without renal failure,
while the non-renal clearance was similar to that in normal sub-
jects. Moreover, it appeared that VD and C1B were dependent on
the dialyzer used and the time of measurement between subse-
quent dialyses. The mean digoxin clearances of the dialyzers,
calculated from the digoxin levels in plasma samples from the
arterial and venous blood lines, were 28.3 and 21.8 ml/min for the
Gambro Lundia® Major and Nova, respectively, while the mean
half-lives were 13.8 and 19.1 hr, respectively. Post-dialysis plasma
concentration data suggest that the rate at which digoxin returns to
plasma from body tissues is the rate-limiting factor in the elimina-
tion of digoxin by the artificial kidney. Because of the time-
dependence of the measured parameters, if can only be said that
these values are roughly in agreement with the pharmacokinetic
data of digoxin in patients on CIH as far as available in literature.
It can be calculated from the measured parameters that: 1) a
suitable digitalization may be obtained with a loading dose of 0.75
mg digoxin iv. and an oral maintenance dose of 0.125 mg digoxin
on days without dialysis; and 2) hemodialysis may be important in
the case of severe digoxin intoxication only during the distribution
phase, i.e., within six hours after ingestion, when much of the drug
still remains in the plasma compartment. In addition, it will be
discussed that literature data indicate that digoxin is preferable to
digitoxin in patients on hemodialysis.
